Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer

Inclusion Criteria:

* Clinically confirmed muscle-invasive bladder cancer.
* Histologically confirmed by HE staining or IHC staining.
* Life expectancy of greater than or equal to 3 months.
* KPS performance \>60, ECOG performance status ≤2.
* Adequate liver function with a bilirubin up to 1.5 x ULN. Transaminases up to 2.5 x ULN; for liver metastasis, transaminases up to 5 x ULN.
* Adequate bone marrow function, as defined by neutrophils count of ≥1.5×109/L, platelet count≥80×109/L, hemoglobin≥9.0g/dL.
* Adequate renal function (serum creatinine ≤1.25 times the ULN, and the release rate of which ≥ 60ml/min).
* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
* Negative serum pregnancy test for female subjects with reproductive potential =\< 7 days prior to registration, for women of childbearing potential only. All female patients of childbearing age and all male patients with partners of childbearing age should use a reliable method of contraception, such as the barrier method, throughout the study and for 8 weeks after last treatment.
* Sign the informed consent before any trial related activities.

Exclusion Criteria:

* A prior malignancy, other than non-melanoma skin cancer, carcinoma in situ, localized prostate cancer or ductal carcinoma in situ treated by surgery unless they have completed therapy at least 5 years prior to start of study and have no evidence of recurrent or residual disease
* Chemotherapy, biological therapy or other anti-cancer drugs ≤ 28 days prior to pre-registration
* Factors that would affect taking medicine orally, such as dysphagia, chronic diarrhea and intestinal obstruction
* History of arterial/venous thrombus ≤ 6 months prior to registration, such as cerebrovascular accident, deep vein thrombosis and pulmonary embolism
* History or tendency of gastrointestinal hemorrhage caused by severe gastroesophageal varices or other reasons.
* Dysfunction of blood coagulation: prothrombin time (PT)\>16s, activated partial thromboplastin time (APTT) \>43s, thrombin time (TT) \>21s, INR \>2, fibrinogen \< 2g/L, bleeding tendency or under thrombolytic or anticoagulant therapy
* Uncontrolled intercurrent illness including, but not limited to:

ongoing or active infection; poor controlled diabetes (FBG \> 10 mmol/L); urine protein ≥++, and UAE \> 1.0g/24h; myocardial ischemia; congestive heart failure; cardiac arrhythmia or cardiac insufficiency; LVEF \< 50%

* Unhealed wounds, ulcers or fractures
* Abuse of psychotropic substances or mentally disturbed
* History of HIV, organ transplantation or any other acquired, congenital immunodeficiency diseases
* Patients evaluated not suitable for the study in the opinion of investigators